Background-Statins stabilize atherosclerotic plaque, decrease mortality after surgical procedures, and are linked to antiinflammatory effects. The objective of this study was to evaluate preoperative administration of statins and longitudinal limb salvage after lower extremity endovascular revascularization and lower extremity open surgery. Methods and Results-Patients were selected from 2007 to 2008 Medicare claims using the International Classification of Diseases, Ninth Revision, Clinical Modification, diagnosis codes for claudication (N=8128), rest pain (N=3056), and ulceration/gangrene (N=11 770) and Current Procedural Terminology codes for endovascular revascularization (N=14 353) and open surgery (N=8601). Half (N=11 687) were identified as statin users before revascularization using Part D files. Amputations were identified using Current Procedural Terminology codes. Statin users compared with nonusers had lower amputation rates at 30 days (11.5% versus 14.4%; P<0.0001), 90 days (15.5% versus 19.3%; P<0.0001), and 1 year (20.9% versus 25.6%; P<0.0001). Survival analysis demonstrated improved limb salvage during 1 year for statin users compared with nonusers for the diagnosis of claudication (P=0.003), a similar trend for rest pain (P=0.061), and no improvement for ulceration/gangrene (P=0.65). Conclusions-Preoperative statins were associated with improved 1-year limb salvage after lower extremity revascularization. The strongest association was found for patients with the diagnosis of claudication. Statins seem to be underused among Medicare patients with peripheral artery disease. Further evaluation of the use of preoperative statins and the potential benefits for peripheral vascular interventions is warranted. (Circ Cardiovasc Interv. 2013;6:694-700.)
A lthough statins are primarily prescribed for their lipidlowering effects, they have many lipid-independent effects, including decreasing inflammation. 1 Beyond reduction of the inflammatory response, statins have also been associated with ability to reduce thrombosis, enhance fibrinolysis, decrease platelet reactivity, inhibit cell growth, reduce ischemia-reperfusion injury, and restore endothelial function. 2 The use of statin therapy preoperatively and their association with reduced postoperative cardiovascular events have been well described in the literature among patients with cardiovascular disease. 3 The Heart Protection Study Collaborative Group Trial, a landmark randomized controlled trial conducted on high-risk surgical patients with cardiovascular disease, established the beneficial outcomes of perioperative statin therapy on cardiovascular patients. 4 Further analysis of a subset population within the Heart Protection Study Collaborative Group Trial determined that these benefits translated to patients with peripheral artery disease (PAD). 5, 6 In addition to cardiovascular benefits on mortality, it has been shown that preoperative statin therapy reduces all-cause mortality in patients with peripheral vascular disease undergoing major noncardiac vascular surgery. 7 Despite this information, few data exist evaluating the effect of statins on limb salvage for patients undergoing peripheral vascular interventions.
Peripheral vascular disease of the lower extremities is often graded clinically by symptomatology-intermittent claudication, rest pain, or ulceration/gangrene-with most patients rarely progressing to limb-threatening disease. 8 Management goals should be aimed at risk factor modifications, with therapy efficacy measured by limb salvage and amputation rates. 9 Using Medicare data, this analysis evaluated the association between statin therapy and limb salvage and amputation in patients undergoing lower extremity (LE) vascular procedures.
Methods

Data Sources
We obtained the following data for the years 2007 
Study Population
We included all Medicare beneficiaries aged ≥65 years with a diagnosis of atherosclerosis of LE arteries who were hospitalized during 2007 to 2008 for LE revascularization. Using the Beneficiary Summary file, we selected individuals who were enrolled in Medicare Part D for the entire calendar year. From this cohort, we used MedPAR data to select those who were hospitalized with a diagnosis of intermittent claudication (ICD-9-CM diagnosis code 440. 21 
Statistical Analysis
We used SAS software, version 9.2 (SAS Institute, Cary, NC) for all analyses. A value of P ≤0.05 was considered statistically significant. We compared patient characteristics by indication using the χ 2 analysis for categorical variables and 1-way ANOVA for continuous variables. Amputation rates and 95% confidence intervals (CIs) were calculated by indication, procedure, and preprocedure statin use.
The difference in the 1-year limb salvage between patients with and without statins was tested with Cox proportional hazards modeling. Covariates included age, sex, race, comorbidities, statin use, and type of procedure (endovascular or open surgery). Each indication (claudication, rest pain, or ulceration/gangrene) was considered in a separate model. Kaplan-Meier survival curves were used to visualize results. The study was approved by the institutional review boards at both institutions.
Results
We identified 22 954 patients who met inclusion criteria. Approximately half (Table 1 ) had LE atherosclerosis with claudication or rest pain; the remainder underwent surgery because of ulceration or gangrene. Endovascular revascularization was performed in 62.5% of all patients; 37.5% patients underwent open surgery.
Patients with claudication were significantly younger than those with rest pain or ulceration/gangrene (P<0.0001). The proportion of patients aged ≥80 years increased with PAD severity (P<0.0001). Overall, women comprised just more than half of the study population (53.3%); among PAD severity groups, those with rest pain (57.0%) or ulceration/gangrene (54.2%) were more likely to be women (P<0.0001). Increasing PAD severity was associated with a decreasing proportion of white patients and an increasing proportion of black patients (P<0.0001). Several comorbid diseases were unequally distributed across the study population: increased PAD severity was associated with an increased proportion of patients with congestive heart failure, diabetes mellitus, or renal failure and a decreased proportion of patients with hypertension or obesity. The use of statins also differed by disease severity. Patients with claudication used statins before surgery more frequently (59.3%) than patients with rest pain (48.9%) or ulceration/ gangrene (45.1%; P<0.0001). Table 2 shows unadjusted amputation rates 30 days, 90 days, and 1 year after LE revascularization in patients who used and did not use statins before surgical intervention. In unadjusted analyses including the entire population, patients who used statins compared with those who did not were less likely to have an amputation within 30 days (relative risk=0.80; 95% CI, 0.75-0.86; P<0.0001), 90 days (relative risk=0.80; 95% CI, 0.76-0.85; P<0.0001), and 1 year (relative risk=0.82; 95% CI, 0.78-0.86; P<0.0001) of revascularization. We found similar differences between statin users and nonusers when we analyzed separately patients who underwent endovascular or open surgery ( Figure 1 ). For both procedure types, statin use was associated with significantly lower amputation rates for all 3 time periods (all P≤0.015). Table 3 shows multivariable Cox regression models for amputation during the year after LE revascularization. Kaplan-Meier survival curves for each indication are shown in Figure 2 . For patients with claudication or ulceration/gangrene, some comorbidities were associated with elevated risk of amputation, including congestive heart failure and renal failure. Diabetes mellitus with chronic complications was associated with elevated risk for all 3 indications, whereas
WHAT IS KNOWN
• The use of statin therapy preoperatively is associated with reduced postoperative cardiovascular events.
• Preoperative statin therapy reduces all-cause mortality in patients with peripheral vascular disease undergoing major noncardiac vascular surgery.
WHAT THE STUDY ADDS
• Identifies that preoperative statins are associated with improved 1-year limb salvage for patients undergoing peripheral vascular interventions.
• Demonstrates that statin therapy is underused among patients with PAD undergoing peripheral interventions in the US Medicare population.
hypertension was associated with reduced risk of amputation for those with rest pain or ulceration/gangrene. For patients with claudication, lack of statin use before surgery was associated with significantly elevated risk of amputation (hazard ratio=1.55; 95% CI, 1.16-2.06; P=0.003), whereas the association just missed statistical significance for patients with rest pain (hazard ratio=1.26; 95% CI, 0.99-1.62; P=0.06). Among patients with ulceration/gangrene, there seemed to be no association between previous statin use and amputation (P=0.65). For patients with claudication, open procedures were also associated with higher risk of amputation (hazard ratio=1.94; 95% CI, 1.45-2.60). Historically, statins have been associated with improved outcomes in the cardiovascular population. [1] [2] [3] [4] In a retrospective cohort study, Pan et al 10 demonstrated that preoperative statin therapy was independently associated with a significant reduction (≈50%) in the risk of 30-day all-cause mortality. They concluded that preoperative statin therapy may reduce the risk of early mortality after primary coronary artery bypass graft surgery with cardiopulmonary bypass. This benefit has translated into the PAD population, with studies suggesting reduction of adverse cardiovascular events, including death, myocardial infarction, and stroke, in patients on preoperative statin therapy. 6 The Statins for Risk Reduction in Surgery (StaRRS) study, a retrospective study for a 2-year period, demonstrated that after adjusting for other significant predictors of perioperative complications, statin therapy was highly protective against perioperative cardiac complications in patients undergoing noncardiac vascular surgery. 11 Furthermore, Poldermans et al 12 found that preoperative statin therapy reduces all-cause mortality in patients undergoing major noncardiac vascular surgery. Data are presented as hazard ratio (95% confidence interval). The suggested mechanism of statins on the outcomes of patients with PAD remains unclear and cannot be addressed in the current study. Authors have suggested that lower plasma low-density lipoprotein cholesterol concentrations for patients on statins may allow plaques to be less occlusive and less likely to rupture and cause thrombosis. 13 Therefore, it has been hypothesized that statins may slow the progression of atherosclerosis, and others have suggested that the addition of lipidlowering treatment may improve local symptoms and reduce the need for reconstructive surgery. 14 When all LE interventions were evaluated in this analysis, patients receiving preoperative statin therapy overall had statistically significant lower amputation rates at 30 days, 90 days, and 1 year after surgery. Aiello et al 15 performed a retrospective review of 346 patients undergoing endovascular treatment for chronic limb ischemia. They determined that patients who received statin therapy when they underwent interventions for the treatment of chronic limb ischemia had significantly improved overall survival, primary and secondary patency, and limb salvage rates, 15 findings that are consistent with our results. Our findings, comparable with those of Aiello et al, 15 suggest that statins should be in the periprocedural treatment regimen and support further investigation into the beneficial effects of statins in patients undergoing treatment for PAD and limb salvage.
In subset analysis, the association between statin usage and limb salvage was stronger for patients with diagnosis of claudication compared with patients with rest pain, whereas there was no association for patients with ulceration/gangrene. Survival analysis demonstrated improved limb salvage during 1 year for statin users compared with nonusers for patients with claudication. The explanation for this finding is unclear because there may be bias in the selection of patients who received statins. Reasons for the disparity of the statin association between claudicants and those patients with rest pain or ulceration/gangrene are not fully understood. It may be secondary to the fact that patients with more severe diagnoses are likely to need amputation sooner, therefore demonstrating less association between statins and amputation in this analysis with 1-year follow-up.
Our study suggests severe underuse of statin therapy in a population where there is sufficient evidence to suggest that compliance with therapy improves outcomes. 9, 16 Chronic statin therapy has been associated with a reduction in all cardiac and vascular outcomes after major vascular surgery. 17 Authors have stated that ideally, statins should be initiated a minimum of 2 weeks before the procedure, 18 and the most recent European Society of Cardiology guidelines suggested initiation of statins in patients undergoing high-risk surgery between 30 days and 1 week before surgery. 19 Our results showing a poor compliance to guidelines and published data are corroborated by a subset analysis of the PREVENT III (PRoject of Ex-Vivo vein graft Engineering via Transfection III) multicenter trial examining baseline characteristics among patients who require infrainguinal revascularization for chronic limb ischemia at elevated risk for cardiovascular events. 20 Among the 1404 patients examined, only 54% of patients were on lipid-lowering medications. Compliance to medications was higher in patients treated in a University setting, suggesting the need for standardization of care. Current evidence implies that statin treatment may also play a beneficial role in the management of patients undergoing percutaneous renal artery revascularization, endovascular abdominal aortic aneurysm repair, and carotid angioplasty/ stenting and endovascular peripheral arterial interventions. 18 Poor compliance and lack of optimal medical management of patients with PAD are common. A prospective trial evaluating 423 patients in >23 vascular clinics across the United Kingdom found that only 44% of patients were on lipidlowering medications. 21 These studies, in conjunction with our results, demonstrate the underuse of evidence-based practice in the patient population with PAD undergoing interventions. Current guidelines recommend that patients who are prescribed statins as chronic therapy should continue treatment in the perioperative period, but our data suggest that there may be benefit from the use of perioperative statins in a wider population. Despite evidence on the beneficial use of statins in patients with PAD, we found that only half of patients with PAD undergoing vascular procedures in the Medicare population were taking statin therapy.
Furthermore, there is the potential effect of statin initiation and compliance with outcomes in the vascular surgery population. Aubert et al 22 evaluated the effect of medication compliance and the possible effect it may have on costs. This analysis evaluating statin prescription refills during the first 2 years after the initial statin claim tracked hospitalizations and direct medical costs during the first 3 years. This study demonstrated that compliance with statin therapy in the first 2 years of use may reduce hospitalization rates and direct medical costs in the subsequent year. Our study suggests that statins may improve patient outcomes and decrease the need for future amputation over time. Nonetheless, there is the potential effect to decrease amputation over time and the subsequent costs with the education of patients and practitioners in the vascular patients, which by definition are at high risk.
Study Limitations
There are limitations to this analysis. The Medicare data are administrative, and refined clinical information such as anatomic detail is limited by the ICD-9-CM and CPT codes. Definition of indications and coding may vary among institutions and coders. As well, certain complications may not be captured in administrative data sets. For this analysis, all statins were considered equivalent, which may not be the case. Furthermore, because we conducted a retrospective analysis of Medicare data, we were unable to discern actual medication compliance and the exact dose consumed by the patients. In addition, because statin therapy was not randomly assigned, between-group differences could introduce selection bias. We were able, however, to control for important confounders such as patient demographics, disease severity, and comorbid conditions. As well, there may be inherent biases to this assessment. Patients who fill prescriptions may be more compliant or have better access to healthcare compared with the nonstatin group, although both groups of patients saw physicians because they had interventions performed. Furthermore, emergent cases might have had worse prognoses, regardless of statin therapy, but may not have had time to initiate statin therapy. Finally, patients with contraindications to statins or those who could not tolerate statins might also have worse outcomes regardless of statin use.
Conclusions
This population evaluation demonstrates that preoperative statins were significantly associated with improved 1-year limb salvage after LE revascularization. The association was stronger for patients with the diagnosis of claudication compared with patients with rest pain or ulceration/gangrene. Furthermore, this study elucidates the underuse of statin therapy among patients with PAD undergoing peripheral interventions in the Medicare population. Further evaluation of preoperative statins and improved education in vascular patients and physicians to optimize medical management before revascularization may increase amputation-free survival.
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